# Safety, Tolerability and Efficacy of TransCon hGH Weekly Versus Daily hGH in Chinese Pediatric Growth Hormone Deficiency

> **NCT04326374** · PHASE3 · UNKNOWN · sponsor: **Visen Pharmaceuticals (Shanghai) Co., Ltd.** · enrollment: 150 (estimated)

## Conditions studied

- Growth Hormone Deficiency
- Endocrine System Diseases
- Hormones
- Pituitary Diseases
- Pituitary Disease, Anterior

## Interventions

- **DRUG:** TransCon hGH
- **DRUG:** daily hGH

## Key facts

- **NCT ID:** NCT04326374
- **Lead sponsor:** Visen Pharmaceuticals (Shanghai) Co., Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2019-12-30
- **Primary completion:** 2022-04
- **Final completion:** 2022-04
- **Target enrollment:** 150 (ESTIMATED)
- **Last updated:** 2020-03-30

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04326374

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04326374, "Safety, Tolerability and Efficacy of TransCon hGH Weekly Versus Daily hGH in Chinese Pediatric Growth Hormone Deficiency". Retrieved via AI Analytics 2026-06-04 from https://api.ai-analytics.org/clinical/NCT04326374. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*